Akeso: all 165 studies

Page 1 of 2. Open to participants first (67), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.Not yet recruitingNCT07883213Phase 2
• A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous UrticariaNot yet recruitingNCT07875426Phase 2
• A Study of AK157D1 for Injection in Advanced Solid TumorsRecruitingNCT07847281Phase 1
• A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNCT07755371Phase 2
• Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Phase 3
• A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruitingNCT07669779Phase 2
• A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial CarcinomaNot yet recruitingNCT07636772Phase 2
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerRecruitingNCT07623356Phase 1/2
• A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsNot yet recruitingNCT07619001Phase 1
• A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerRecruitingNCT07591090Phase 2
• A Phase I Clinical Study of AK150 in Advanced Malignant Solid TumorNot yet recruitingNCT07566247Phase 1
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerNot yet recruitingNCT07560124Phase 1/2
• A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)RecruitingNCT07547787
• A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic DermatitisNot yet recruitingNCT07502222Phase 2
• A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07449780Phase 3
• A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic RhinitisNot yet recruitingNCT07436234Phase 2
• A Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaNot yet recruitingNCT07436221Phase 2
• Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingNCT07412613Phase 3
• A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruitingNCT07357220Phase 1/2
• A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s DiseaseNot yet recruitingNCT07301502Phase 1
• A Study of AK138D1 in Advanced Malignant TumorsRecruitingNCT07281326Phase 1
• Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)RecruitingNCT07263919Phase 2
• A Study of Ivonescimab in First-Line ES-SCLCRecruitingNCT07245446Phase 2
• AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) TreatmentNot yet recruitingNCT07158840Phase 2
• A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic CancerRecruitingNCT07114315Phase 2
• A Study of AK146D1 for Injection in Advanced Solid TumorsRecruitingNCT07067567Phase 1
• A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Phase 2
• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Phase 3
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Phase 3
• A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• AK112 and Chemotherapy in First-line Metastatic Colorectal CancerRecruitingNCT06951503Phase 3
• A Clinical Study of AK139 in Healthy SubjectsNot yet recruitingNCT06947109Phase 1
• AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
• A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerRecruitingNCT06938321Phase 1/2
• A Study of AK146D1 for Injection in the Treatment of Advanced Solid TumorsRecruitingNCT06929663Phase 1
• Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
• A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACNot yet recruitingNCT06913218Phase 1
• AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)Not yet recruitingNCT06860789Phase 1
• A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic DermatitisNot yet recruitingNCT06767540Phase 3
• AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerRecruitingNCT06767527Phase 3
• A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)Not yet recruitingNCT06756126Phase 2
• A Phase I Study of AK138D1 in the Treatment of Advanced Solid TumorsRecruitingNCT06730386Phase 1
• AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant TumorsNot yet recruitingNCT06691360Phase 1
• Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2
• A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingNCT06642792Phase 1/2
• A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male SubjectsNot yet recruitingNCT06641388Phase 1
• A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCRecruitingNCT06617416Phase 3
• A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)RecruitingNCT06601335Phase 3
• An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecruitingNCT06560112Phase 2
• A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Phase 1/2
• A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaNot yet recruitingNCT06387420Phase 1/2
• A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT06383468Phase 3
• A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
• A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06341335Phase 3
• A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesRecruitingNCT06196203Phase 2
• A Study of AK131 in Patients With Advanced Solid TumorsRecruitingNCT06166888Phase 1
• A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid TumorNot yet recruitingNCT06166472Phase 1
• A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Phase 3
• Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT05960955Phase 2
• A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant TumorsRecruitingNCT05868876Phase 1
• A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerRecruitingNCT05859750Phase 2
• Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsRecruitingNCT05689853Phase 1/2
• A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Phase 3
• A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's LymphomaRecruitingNCT05244642Phase 3
• A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsRecruitingNCT05142423Phase 1/2
• A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04982276Phase 1/2
• A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male SubjectsActive, not recruitingNCT07340476Phase 1
• A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese SubjectsCompletedNCT07043283Phase 1
• A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic DermatitisCompletedNCT06700499Phase 2
• AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerActive, not recruitingNCT06646055Phase 1/2
• AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerActive, not recruitingNCT06591520Phase 3
• A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ AdenocarcinomaCompletedNCT06586294Phase 1/2
• A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisCompletedNCT06378697Phase 3
• A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT06281704Phase 1
• A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic DermatitisCompletedNCT06092762Phase 2
• A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT06066125Phase 3
• To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque PsoriasisCompletedNCT06061471Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic DermatitisCompletedNCT06035354Phase 1/2
• A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsActive, not recruitingNCT05951608Phase 1/2
• AK104 for Recurrent or Metastatic Vulvar CancerTerminatedNCT05932212Phase 2
• AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05904379Phase 1/2
• A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal CancerActive, not recruitingNCT05846867Phase 1/2
• AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
• A Study of AK130 in Patients With Advanced Malignant TumorsCompletedNCT05653284Phase 1
• A Study of AK129 in Patients With Advanced Malignant TumorsCompletedNCT05645276Phase 1
• Study of AK119 and AK112 With or Without Chemotherapy for NSCLC PatientsTerminatedNCT05636267Phase 1/2
• A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male SubjectsCompletedNCT05559554Phase 1
• Study of AK119 Combined With AK104 in Patients With Advanced Solid TumorsTerminatedNCT05559541Phase 1/2
• Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With PsoriasisCompletedNCT05509361Phase 3
• A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerCompletedNCT05505825Phase 1/2
• A Study of AK111 in Subjects With Moderate-to-severe Plaque PsoriasisCompletedNCT05504317Phase 1
• AK112 in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT05499390Phase 3
• A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisCompletedNCT05467995Phase 2
• A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT05432492Phase 2
• A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid TumorsStatus unknownNCT05393063Phase 1
• A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerActive, not recruitingNCT05382442Phase 2
• A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2
• A Clinical Study of AK115 in Healthy SubjectsCompletedNCT05286970Phase 1
• A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With HyperlipidemiaCompletedNCT05260411Phase 3

← Akeso overview and focus areas